tbuckley/cabot-search huggingface dataset:
Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost‐effectiveness analysis
Authors: Matthew J. Klebanoff, Kathleen E. Corey, Jagpreet Chhatwal, Lee M. Kaplan, Raymond T. Chung, Chin Hur
Journal: Hepatology (2016)

Nonalcoholic steatohepatitis (NASH) affects 2%‐3% of the US population and is expected to become the leading indication for liver transplantation in the next decade. Bariatric surgery may be an effective but expensive treatment for NASH. Using a state‐transition model, our analysis assessed the effectiveness and cost‐effectiveness of surgery to manage NASH. We simulated the benefits and harms of laparoscopic Roux‐en‐Y gastric bypass surgery in patients defined by weight class (overweight, mild obesity, moderate obesity, and severe obesity) and fibrosis stage (F0‐F3). Comparators included intensive lifestyle intervention (ILI) and no treatment. Quality‐adjusted life years (QALYs), costs, and incremental cost‐effectiveness ratios were calculated. Our results showed that surgery and ILI in obese patients (with F0‐F3) increased QALYs by 0.678‐2.152 and 0.452‐0.618, respectively, compared with no treatment. Incremental cost‐effectiveness ratios for surgery in all F0‐F3 patients with mild, moderate, or severe obesity were $48,836/QALY, $24,949/QALY, and $19,222/QALY, respectively. In overweight patients (with F0‐F3), surgery increased QALYs by 0.050‐0.824 and ILI increased QALYs by 0.031‐0.164. In overweight patients, it was cost‐effective to reserve treatment only for F3 patients; the incremental cost‐effectiveness ratios for providing surgery or ILI only to F3 patients were $30,484/QALY and $25,367/QALY, respectively. Conclusions : Surgery was both effective and cost‐effective for obese patients with NASH, regardless of fibrosis stage; in overweight patients, surgery increased QALYs for all patients regardless of fibrosis stage, but was cost‐effective only for patients with F3 fibrosis; our results highlight the promise of bariatric surgery for treating NASH and underscore the need for clinical trials in this area. (H epatology 2017;65:1156‐1164).
Genetic Basis of Primary Central Nervous System Lymphoma
Authors: Kenichi Yoshida, Rie Nakamoto-Matsubara, Kenichi Chiba, Yusuke Okuno, Nobuyuki Kakiuchi, Yuichi Shiraishi, Yusuke Sato, Hiromichi Suzuki, Tetsuichi Yoshizato, Yusuke Shiozawa, Keisuke Kataoka, Hiroo Ueno, June Takeda, Yasunobu Nagata, Hiroko Tanaka, Yasuo Iwadate, Hiroaki Hondoh, Junya Fukai, Koji Kajiwara, Makoto Ideguchi, Yoshihiro Komohara, Yukihiko Fujii, Syunichi Kohriyama, Masayuki Nitta, Yoshiharu Muragaki, Mamiko Sakata-Yanagimoto, Shingo Suzuki, Takashi Shiina, Satoru Miyano, Shigeru Chiba, Yamanaka Ryuya, Seishi Ogawa
Journal: Blood (2015)
Seeing beyond 2020: an economic evaluation of contemporary and emerging strategies for elimination of Trypanosoma brucei gambiense
Authors: C Simone Sutherland, Christopher M Stone, Peter Steinmann, Marcel Tanner, Fabrizio Tediosi
Journal: The Lancet Global Health (2016)

Trypanosoma brucei (T b) gambiense is targeted to reach elimination as a public health problem by 2020 and full elimination by 2030. To achieve these goals, stakeholders need to consider strategies to accelerate elimination. Hence, we aimed to model several options related to current and emerging methods for case detection, treatment, and vector control across settings to assess cost-effectiveness and the probability of elimination.Five intervention strategies were modelled over 30 years for low, moderate, and high transmission settings. Model parameters related to costs, efficacy, and transmission were based on available evidence and parameter estimation. Outcomes included disability-adjusted life-years (DALYs), costs, and long-term prevalence. Sensitivity analyses were done to calculate the uncertainty of the results.To reach elimination targets for 2020 across all settings, approaches combining case detection, treatment, and vector control would be most effective. Elimination in high and moderate transmission areas was probable and cost-effective when strategies included vector control and novel methods, with incremental cost-effectiveness ratios (ICERs) ranging from US$400 to $1500 per DALY averted. In low transmission areas, approaches including the newest interventions alone or in combination with tiny targets (vector control) were cost-effective, with ICERs of $200 or $1800 per DALY averted, respectively, but only strategies including vector control were likely to lead to elimination. Results of sensitivity analyses showed that allowing for biennial surveillance, reducing vector control maintenance costs, or variations of active surveillance coverage could also be cost-effective options for elimination, depending on the setting.Although various strategies might lead to elimination of T b gambiense, cost-effective approaches will include adoption of emerging technologies and, in some settings, increased surveillance or implementation of vector control.Bill & Melinda Gates Foundation.
Cardiac Myofibroblasts of Hematopoietic Origin Are Mobilized by G-CSF and Contribute to Cardiac Repair after Myocardial Infarction.
Authors: Hiroshi Kawada, Jun Fujita, Mitsuyo Tsuma, Yumi Matsuzaki, Hideyuki Okano, Keiichi Fukuda, Tomomitsu Hotta, Kiyoshi Ando
Journal: Blood (2005)
Postoperative Pulmonary Complications—A Multifactorial Outcome
Authors: Krista L. Haines, Suresh Agarwal
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Initial Clinical Findings From a Population-Based Study of Adult Myelodysplastic Syndrome: Discordance Between World Health Organization (WHO) Classifications
Authors: Erica D Warlick, Phuong L. Nguyen, Adina Cioc, Betsy A. Hirsch, Jeffrey S. Miller, Daniel J. Weisdorf, Michelle A. Roesler, Jessica Musselman, Julie A. Ross
Journal: Blood (2011)
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups
Authors: Pierre WijerMans, Stefan Suciu, Liliana Baila, Uwe Platzbecker, Aristoteles Giagounidis, Dominik Selleslag, Boris Labar, Helmut Salih, Filip Beeldens, Petra Muus, Theo de Witte, Michael Lübbert
Journal: Blood (2008)
Prior Autologous Hematopoietic Cell Transplantation Confers an Adverse Prognosis for Recipients of Allogeneic Transplantation Following Nonmyeloablative Preparative Conditioning.
Authors: Gary J. Schiller, Christos Emmanouilides, Ron Paquette, Peter Rosen, Jennifer Gansert, Mary C. Territo
Journal: Blood (2004)
The Elevated Ratio of Peripheral Blood CD27−CD4+ T Cells in Patients Received Allogeneic Stem Cell Transplantation Implies Altered T Cell Homeostasis.
Authors: Akiko Fukunaga, Takayuki Ishikawa, Takero Shindo, Sumiko Takao, Toshiyuki Hori, Takashi Uchiyama
Journal: Blood (2005)
Evaluation of Romiplostim In a Randomized Placebo-Controlled Phase 3 Study of a Japanese Population with Chronic Immune Thrombocytopenia (ITP).
Authors: Koji Miyazaki, Yukari Shirasugi, Kiyoshi Ando, Yoshiaki Tomiyama, Shinichiro Okamoto, Mineo Kurokawa, Keita Kirito, Yuji Yonemura, Shinichiro Mori, Kensuke Usuki, Koji Iwato, Satoshi Hashino, Helen Wei, Richard Lizambri
Journal: Blood (2010)
PWE-003 Ileostomy Formation as A Result of Surgical Management for Crohn’s Disease: A Qualitative Study
Authors: A Morris, B Leach
Journal: Gut (2016)

<h3>Introduction</h3> Ileostomy formation for severe Crohn’s Disease (CD) brings physical and psychosocial sequelae requiring people to self-manage numerous lifestyle changes. However pre and post formation experiences of an ileostomy and adaptation are underexplored. This qualitative study explores the experiences of adults with CD pre and post ileostomy formation. <h3>Methods</h3> A phenomenological design utilised in-depth semi-structured interviews with adults with Crohn’s and ileostomy. Convenience sample recruitment via Coventry Iileostomy and Internal Pouch Support Group was employed. A topic guide covered the areas of life before and after an ileostomy and feelings about the support received. Interviews were recorded and transcribed verbatim. Data was explored and findings interpreted using Framework Analysis. NVIVO software was used for data management. Member checking and internal peer review were undertaken. Participants gave written informed consent. <h3>Results</h3> Ten adults (4 men 6 women) with a mean age of 52.2 (±19) years had a mean experience of 18.8(±11.4) years of living with an ileostomy. Three major themes emerged: (1) Controlling nature of Crohn’s embodied by pain, diarrhoea, vomiting, and low mood as a life “not worth living” (2) New life post stoma formation facilitated “total freedom” and re-engagement with work/socialising (as a result, individuals “refused to have the ileostomy reversed”) (3) Peer support along with clinical nutrition updates would have helped as “people doing it themselves understand”. One minor theme emerged around a new life: (2 a) memories of CD affected life with an ileostomy. These experiences meant that certain health promoting behaviours, for example, intentional weight loss for corticosteroid/ smoking cessation induced weight gain, were avoided as individuals were “not going back to a walking skeleton” pre stoma formation. <h3>Conclusion</h3> Life with Crohn’s was debilitating before an ileostomy. Individuals viewed ileostomy construction as a positive experience as the stoma helped manage the CD symptoms. Memories of life pre-ileostomy may affect individuals’ behaviour post-ileostomy formation. Implications for clinical practice include multi-disciplinary team (MDT) members understanding that memories of CD may still affect health related behaviour post stoma formation which may require further MDT support. <h3>Disclosure of Interest</h3> None Declared
Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized by Thymic Regeneration Failure.
Authors: Krishna V. Komanduri, Lisa S. St. John, Susan Bryan, Sean Martin, John D. McMannis, Jeffrey J. Molldrem, Richard E. Champlin, Laurence J. Cooper, Laura Worth, Demetrios Petropoulos, Daniel R. Couriel, Marcos de Lima, Elizabeth J. Shpall
Journal: Blood (2006)
Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.
Authors: Jorge Cortes, Susan O’Brien, Srdan Verstovsek, George Daley, Charles Koller, Alessandra Ferrajoli, Odeal Pate, Stefan Faderl, Farhad Ravandi-Kashani, Moshe Talpaz, Yali Zhu, Paul Statkevich, Mary Sugrue, Hagop Kantarjian
Journal: Blood (2004)
Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study
Authors: Eric D Hsi, Jonathan Said, Jeffrey L Johnson, Sinho Jung, Raymond Lai, Dan Jones, Amy Chadburn, Bruce D. Cheson, Wyndham H. Wilson
Journal: Blood (2008)
Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa
Authors: Roch Houot, Carole Soussain, Hervé Tilly, Corinne Haioun, Catherine Thieblemont, Olivier Casasnovas, Krimo Bouabdallah, Franck Morschhauser, Steven Le Gouill, Gilles A. Salles, Tony Marchand, Céline Pangault, Camille Laurent, Thierry Lamy
Journal: Blood (2015)
Enhanced Serum Complement Activation on Platelets Is Associated with Arterial Thrombosis in Patients with Systemic Lupus Erythematosus (SLE) and Antiphospholipid Antibodies(aPL).
Authors: Ellinor I.B. Peerschke, Wei Yin, Deborah R. Alpert, Jane E. Salmon, Robert A.S. Roubey, Berhane Ghebrehiwet
Journal: Blood (2007)
New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma
Authors: Ola Landgren, S. Vincent Rajkumar
Journal: Clinical Cancer Research (2016)

Abstract Over the past few years, the management of multiple myeloma has changed. We have new guidelines regarding how to set the diagnosis, when to initiate therapy, and how to monitor treatment response. In 2014, the updated International Myeloma Working Group (IMWG) diagnostic criteria changed the definition of multiple myeloma from being a disease defined by symptoms to a disease defined by biomarkers. Today, modern combination therapies have reported up to 60% to 80% of patients reaching a complete response. As a logical and necessary step forward, investigators have explored strategies to detect minimal residual disease (MRD) and its correlation with clinical outcomes. Recent meta-analysis data show that MRD negativity is associated with longer progression-free survival and overall survival. In 2016, the updated IMWG response criteria include MRD as the deepest level of treatment response in multiple myeloma. Simultaneously, we are still quite behind in our understanding of the heterogeneous biology of multiple myeloma and its implications for therapy. Emerging DNA sequencing data show that newly diagnosed multiple myeloma patients have a broad range of mutations, which are distributed unevenly in multiple parallel subclones already present at diagnosis. To move beyond the ill-defined category of “high-risk multiple myeloma,” which confers to approximately 25% of all newly diagnosed patients, prospective studies are needed to dissect tumor biology and define multiple myeloma subtypes, and, based on biology, seek to define rational therapies for individual subtypes. This article discusses novel insights and gives perspectives on diagnosis and MRD monitoring and future directions for prognosis and clinical management of multiple myeloma. Clin Cancer Res; 22(22); 5428–33. ©2016 AACR. See all articles in this CCR Focus section, “Multiple Myeloma: Multiplying Therapies.”
Comparison Of BCR-ABL1/ABL1 and BCR-ABL1/GUS Ratios At Different Clinical Decision Cut-Offs In Chronic Phase Chronic Myelogenous Leukemia Patients On Imatinib
Authors: Sarah Huet, Denis Souche, Jean-Pierre Magaud, Pascale Cony-Makhoul, Yann Guillermin, Mael Heiblig, Mauricette Michallet, Franck E. Nicolini, Sandrine Hayette
Journal: Blood (2013)
A Population Based Study of 408 Cases of Acute Promyelocytic Leukemia Showing Changes in Epidemiology and Prognosis During Two Decades: Impact of Oral Arsenic Trioxide,
Authors: Wing-Yan Au, Dennis Ip, Oscar Mang, Kit Fai Wong, Margaret Ng, Thomas SK Wan, Eudora Chow, Michael LG Wong, Chi Kuen Lau, Bhonnie Kho, Ching Wa Lau, Edmond SK Ma, Cyrus Kumana, Yok Lam Kwong
Journal: Blood (2011)
PWE-138 The Value of The Straight to Test (STT) Specialist Nurse in Expediting Patients Referred on A Routine Pathway with Red Flag, Lower Gastrointestinal (LGI) Symptoms To A Diagnostic Endoscopy Procedure
Authors: L Steward, P Andrews, E Seward, M Machesney, A Wong
Journal: Gut (2016)

<h3>Introduction</h3> Our Trust has a well-established STT service to reduce the wait until a definitive diagnostic test in patients with LGI symptoms. STT receives routine18 Week Wait (18 WW) referrals through Choose and Book with a patient- controlled 3 week window. GPs, therefore, currently refer non-target patients to the service. Patients referred on the pathway wait an average of 31 days for procedure (range 13–44). However, it was found from triage assessment that some patients needed to be fast-tracked and investigated within 2 weeks due to the onset and severity of their symptoms, particularly patients with symptoms suggestive of inflammatory bowel disease (IBD). <h3>Methods</h3> Routine referrals are vetted and prioritised by specialist colorectal nurses using information from the GP referral letter and patient-reported history during telephone assessment. Triage is based on a structured algorithm following 2 Week Wait (2 WW) and National Institute of Clinical Evidence (NICE) guidelines and a symptom questionnaire is completed. A prospective database captures patients’ symptoms, outcomes of triage, procedures and demographic details. Patients with red flag symptoms referred on a routine pathway were expedited and their outcomes documented. Chi Square statistics were applied to test for significance of findings. <h3>Results</h3> 569 patients have been triaged since we began formally fast-tracking (August 2014) .Of those patients, 104 (18%) have been expedited following telephone assessment. 57% of those fast-tracked were female and the mean age was 58 years (range 18–88 yrs). 79% underwent colonoscopy, 3% had a flexible sigmoidoscopy, 1% were referred for an ultrasound scan and 17% were directed for an initial clinic review. The mean number of days from triage to test was 5, which is a 96.5% time-saving on the 18 WW pathway. Of all the patients fast-tracked, 65% had pathology, of which 14% had IBD (age range 18–57 yrs with mean of 39 yrs), compared to 45% pathology findings in routine referrals <i>(p-value &lt;</i><i>0.01</i><i>)</i>, of which 5% had IBD. The chart below shows the findings at endoscopy: <h3>Conclusion</h3> These data suggest that there is a benefit to having a comprehensive history taken by a colorectal specialist nurse in determining the patient pathway in a timely way for diagnosis and start of treatment. With 14% of patients expedited found to have new-onset IBD, the result was prompt treatment of symptoms, and potential avoidance of a hospital admission. <h3>Disclosure of Interest</h3> None Declared
AB0337 Incidence Rate of Tuberculosis in Rheumatoid Arthritis Patients Treated with TNF-α Inhibitors-Data from The Slovenian National bioRx.si Registry: Table 1
Authors: Ž. Rotar, M. Tomsic
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Treatment with TNF-α inhibitors (TNFi) is associated with an increased incidence rate (IR) of tuberculosis (TB).<sup>1</sup> Proper screening can reduce TB IR.<sup>2,3</sup> Recent reports suggest comparable TB IR for certolizumab (CZP) and monoclonal TNF-α inhibiting antibodies adalimumab ADA, golimumab (GOL) and infliximab (IFX) (0.47–0.69 vs 0.29–0.50 per 100 person years (PY), respectively).<sup>4</sup> Etanercept (ETA) was associated with a TB IR of 0.009–0.08 per 100 PY.<sup>5–7</sup> In February 2012 we showed that in our setting with a background annual TB IR of 8.4 per 10<sup>5</sup> persons and stringent screening for latent tuberculosis infection prior to the initiation of the first TNFi since 2002 a TB IR of 0.16 (95% CI 0.02–0.58) per 100 PY in RA patients treated with TNFi.<sup>8</sup> <h3>Objectives</h3> To compare the TB IR in patients treated for RA with different TNFi. <h3>Methods</h3> In February 2015 we cross-linked the data from the mandatory BioRx.si and the national TB registries to identify cases of TB in patients who were ever treated with TNFi to avoid underreporting. TB IR for RA patients were calculated and compared for different TNFi. <h3>Results</h3> At the time of data extraction the BioRx.si contained data for 1693 RA, ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients treated with at least one TNFi for 4574 PY. There were no TB cases among the patients with AS and PsA. In 945 RA patients treated with TNFi for 2453 PY (41% ADA, 9% CZP, 36% ETA, 4% GOL, 10% IFX) 5 cases of TB were identified (Table 1) which translates into an overall IR of 0.20 (95%CI 0.07–0.47) in RA patients. There were no TB cases in RA patients on GOL or IFX, but 3 on CZP, 1 on ADA, and 1 on ETA. The TB IR for CZP was 1.39 (95% CI 0.29–4.02) per 100 PY which is significantly higher than TB IR for ADA at 0.10 (95% CI 0.002–0.55; p=0.002) per 100 PY or ETA at 0.11 (95% CI 0.003–0.63; p=0.005) per 100 PY or all TNFi other than CZP combined at 0.09 (95% CI 0.01–0.32; p=0.006) per 100 PY. <h3>Conclusions</h3> In our TNFi treated observational RA cohort, admitting all the shortcomings of the registry data, we observed a very strong signal suggesting a significantly higher TB IR in patients treated with CZP than those treated with any other TNFi. <h3>References</h3> Gόmez-Reino JJ et al. Arthritis Rheum 2003;48:2085–91. Carmona L et al. Arthritis Rheum 2005;52:1766–72. Gόmez-Reino JJ et al. Arthritis Rheum 2007;57:756–61. Ramiro S et al. Ann Rheum Dis 2010;69:522–8. Askling J et al. Arthritis Rheum 2005;52:1986–92. Tubach F et al. Arthritis Rheum 2009;60:1884–94. Dixon WG et al. Ann Rheum Dis 2010;69:522–8. Tomsic M et al. Ann Rheum Dis 2012;71:1909–11. <h3>Disclosure of Interest</h3> None declared
AB1069 The Educational Needs of People with Spondyloarthropathies (AS and PSA): A Cross-Sectional Study: Table 1.
Authors: M.L. Marques, R. Ferreira, M. Santiago, A. Marques, P.M. Machado, J.A.P. da Silva, M. Ndosi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) have significant impact on patients9 lives and patient education is integral to the management of the diseases. <h3>Objectives</h3> To assess the self-reported educational needs of patients with AS and PsA, and test differences across gender, age, disease duration and educational background. <h3>Methods</h3> In this cross-sectional study, patients completed the Portuguese version of the Educational Needs Assessment Tool (PortENAT). Data was then Rasch-transformed to obtain interval-level measures of their educational needs which were summarized descriptively. Univariable analyses were used to determine differences between patient subgroups. <h3>Results</h3> The study included 121 AS and 132 PsA patients (mean age =47.3 and 53.8 years; disease duration =15.6 and 14.4 years, respectively). Overall, patients with AS had higher educational needs than those with PsA (Table 1). On the domains9 scores, age, gender and educational background had different effects in the disease groups; gender affected all domains, except treatments and support systems, with women expressing higher educational needs. Educational background had the strongest effect on overall score – higher education being related to higher educational needs. <h3>Conclusions</h3> The educational needs vary by disease and demographic characteristics. Assessing individual patient education needs with tools such as the PortENAT may help target individual patient education. <h3>Disclosure of Interest</h3> None declared
Nonmyeloablative Hematopoietic Stem Cell Transplantation Improves a Marker of Diastolic Dysfunction in Patients with Sickle Cell Disease
Authors: Courtney Fitzhugh, Hwaida Hannoush, Vandana Sachdev, Rosario Di Maggio, Wynona Coles, Mary Link, Evan Katradis, Xiongce Zhao, John F. Tisdale, Matthew Hsieh
Journal: Blood (2014)
Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis
Authors: Nicole M. Kettner, Horatio Voicu, Milton J. Finegold, Cristian Coarfa, Arun Sreekumar, Nagireddy Putluri, Chinenye A. Katchy, Choogon Lee, David D. Moore, Loning Fu
Journal: Cancer Cell (2016)
Venous Thromboembolism and Non-Small Cell Lung Cancer: A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trials.
Authors: Lisa Hicks, Matthew Cheung, Baktiar Hasan, Keyue Ding, Lesley Seymour, Natasha B. Leighl, Timothy L. Winton, Frances A. Shepherd
Journal: Blood (2007)